Bioretec Ltd Successfully Completes Oversubscribed Rights Issue Raising Over €9 Million

Bioretec Ltd's Successful Rights Issue



On June 24, 2025, Bioretec Ltd, a pioneer in biodegradable orthopedic implants, announced the final results of its recent rights issue. The event marked a significant milestone in the company's journey towards enhancing bone growth and accelerating fracture healing.

The rights issue was met with overwhelming interest, resulting in a total subscription of 7,658,836 new shares, representing about 124.4% of the 6,156,618 shares originally offered. This oversubscription highlights the market's confidence in Bioretec's innovative technologies and growth prospects. Of the total subscriptions, approximately 79.3% were made using subscription rights, while the remainder was allocated to those who participated in the secondary subscription under the terms of the offering.

The subscription price was set at EUR 1.50 per share, making the total proceeds from the offering approximately EUR 9.2 million. This influx of capital is crucial for Bioretec, as it looks to expand its product line and strengthen its position in the global orthopedic market.

Following the completion of the rights issue, the company's Board of Directors approved the subscriptions and allocated the new shares accordingly. The issuance will increase Bioretec's total share count from 24,626,474 to 30,783,092 shares, with the new shares accounting for approximately 20% of the company's total outstanding shares.

Trading for interim shares on Nasdaq First North Growth Market Finland is set to end on June 26, 2025. Bioretec plans to register the new shares with the Finnish Trade Register on the same date, with full trading of the new shares commencing shortly thereafter on June 27, 2025. Once registered and delivered to investors, these new shares will provide the same rights as existing shares, thereby adding value to shareholders.

Additionally, the Board has approved adjustments to the subscription prices related to Bioretec's stock options to account for the dilutive effects of this rights issue. These adjustments are contingent upon the registration of the new shares, with announcements expected to follow.

The joint global coordinators for the offering, Danske Bank A/S and DNB Carnegie Investment Bank AB, have played critical roles in facilitating this process, ensuring that Bioretec's growth path is well-funded and strategically outlined. Legal counsel was provided by Krogerus Attorneys Ltd and Borenius Attorneys Ltd, and Bravura Ltd is advising on communications.

Bioretec continues to emerge as a leader in the medical device field, focusing on biodegradable orthopedic products that offer remarkable benefits when compared to traditional titanium implants. Their RemeOs™ product line, consisting of magnesium alloy and hybrid composites, exemplifies next-generation technology aimed at improving surgical outcomes. As these biodegradable implants are absorbed and replaced by bone, they eliminate the need for secondary removal surgeries, offering a holistic solution that aligns with modern Value-Based Healthcare objectives.

With a market authorization recently obtained in the U.S. and CE mark approval in Europe for RemeOs™, Bioretec positions itself to tap into the vast USD 10 billion global orthopedic trauma and spine market.

In summary, Bioretec Ltd's successful rights issue sets the stage for its future innovations in orthopedic medicine, and reaffirms its commitment to delivering solutions that enhance the healing journey for patients globally. As the company moves forward, it does so with the backing of an enthusiastic investment community and a clear vision for growth.

For more information about Bioretec and its offerings, visit www.bioretec.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.